true
--12-31
0001847345
0001847345
2026-04-15
2026-04-15
0001847345
ASBP:CommonStockParValue0.0001PerShareMember
2026-04-15
2026-04-15
0001847345
ASBP:WarrantsEachExercisableForOneShareOfCommonStockMember
2026-04-15
2026-04-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 15, 2026
Aspire
Biopharma Holdings, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
| Delaware |
|
001-41293 |
|
33-3467744 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
No.) |
|
(I.R.S.
Employer
Identification
No.) |
23150
Fashion Drive, Suite 232
Estero,
Florida 33928
(Address
of Principal Executive Offices)
(415)
592-7399
(Registrant’s
Telephone Number)
194
Candelaro Drive, #233
Humacao,
PR 00791
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
stock, par value $0.0001 per share |
|
ASBP |
|
The
Nasdaq Stock Market LLC |
| Warrants,
each exercisable for one share of common stock |
|
ASBPW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
EXPLANATORY
NOTE
This
Amendment No. 1 to the Current Report on Form 8-K amends and restates the Current Report on Form 8-K, filed on April 16, 2026, in
order to correct certain disclosure inaccuracies.
Item
1.01. Entry into a Material Definitive Agreement.
Securities
Purchase Agreement
As
previously reported, in the Company’s Current Report on Form 8-K filed on February 6, 2026 (the “February 8-K”),
Aspire Biopharma Holdings, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities
Purchase Agreement”) with certain accredited investors (the “Investors”), providing for a private placement
(the “Offering”), of up to 25,000 shares of Series A Convertible Preferred Stock (the “Preferred Stock”),
convertible into shares of the Company’s common stock (the “Common Stock”). The terms of the Securities Purchase
Agreement, the Preferred Stock, and the related Certificate of Designations, Preferences and Rights of the Series A Convertible Preferred
Stock, as amended (the “Certificate of Designation”) are described in the February 8-K and are incorporated herein
by reference. This Current Report on Form 8-K reports the closing of the second tranche of the Offering.
The
Securities Purchase Agreement and Registration Rights Agreement were previously filed as Exhibits 10.1 and 10.2, respectively, to the
February 8-K and are incorporated herein by reference. The summary of the terms of the Certificate of Designation and the Securities
Purchase Agreement and Registration Rights Agreement in the February 8-K are subject to, and qualified in their entirety by, the full
text of such documents, which are incorporated herein by reference from the February 8-K.
No
statement in this report or the attached exhibits is an offer to sell or a solicitation of an offer to purchase the Company’s securities,
and no offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
The
Offering
As
previously disclosed, on February 6, 2026, the Company closed the first tranche of the Offering for an aggregate of 13,750 Shares, resulting
in gross proceeds of $11,000,000 including the conversion of $943,801 in existing debt into Shares on the same terms. On April 15, 2026,
the Company and the investors closed on the second tranche of the Offering for an aggregate of 12,500 Shares, resulting in gross proceeds
of approximately $10,000,000. In both tranches, gross proceeds are before deducting fees to be paid to the placement agents and financial
advisors of the Company and other estimated offering expenses payable by the Company. Proceeds from the $21,000,000 Offering net
of transaction fees and expenses will be available to fund the cash component of the proposed Dura Driver Control Systems acquisition
and for general corporate purposes.
RBW
Capital Partners acting through Dawson James Securities Inc., served as placement agent on the transaction.
Item
5.03. Amendments to Articles of Incorporation or Bylaws: Change in Fiscal Year.
On
April 13, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Certificate
of Designation of Series A Convertible Preferred Stock (the “Certificate of Amendment”).
The
Certificate of Amendment amends the Company’s previously filed Certificate of Designation of Series A Convertible Preferred Stock,
which was originally filed on February 2, 2026.
Pursuant
to the Certificate of Amendment, the Company amended certain provisions of the Certificate of Designation, including clarifying and restating
provisions relating to the designation and number of shares of Series A Convertible Preferred Stock. As amended, the Company has designated
30,000 shares of Series A Convertible Preferred Stock, each with a par value of $0.0001 and a stated value of $1,000 per share.
Except
as expressly modified by the Certificate of Amendment, the Certificate of Designation remains in full force and effect.
The
foregoing description of the Certificate of Amendment is qualified in its entirety by reference to the full text of the Certificate of
Amendment, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Forward-Looking
Statements
This
Current Report on Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of
1995, including without limitation statements regarding the Company’s intended use of the net proceeds from the Offering. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important
factors that could cause actual results to differ materially include: risks associated with market conditions; risks associated with
the Company’s cash needs; and risks and uncertainties associated with the Company’s business and finances in general; and
other risks and uncertainties set forth from time to time in the Company’s filings with the Commission. Any forward-looking statements
contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company expressly disclaims any obligation to
update any forward-looking statements, whether because of new information, future events or otherwise.
Item
9.01 Financial Statements and Exhibits.
| Exhibit
Number |
|
Description |
| 3.1 |
|
Certificate of Amendment to the Certificate of Designation of Series A Convertible Preferred Stock, filed with the Secretary of State of the State of Delaware on April 13, 2026 |
| |
|
|
| 10.1 |
|
Form of Securities Purchase Agreement, dated February 6, 2026 by and among Aspire Biopharma Holdings, Inc. and the purchasers named therein (incorporated by reference to the current report on Form 8-K, filed on by the Company on February 12, 2026) |
| |
|
|
| 10.2 |
|
Form of Registration Rights Agreement, dated February 6, 2026 by and among Aspire Biopharma Holdings, Inc. and the holders named therein (incorporated by reference to the current report on Form 8-K, filed on by the Company on February 12, 2026) |
| |
|
|
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
ASPIRE
BIOPHARMA HOLDINGS, INC. |
| |
|
|
| |
By: |
/s/
Ernest Scheidemann |
| |
|
Ernest
Scheidemann |
| |
|
Chief
Financial Officer |
| |
|
|
| Date:
April 17, 2026 |
|
|
